KR950016759A - Antibiotic Anticancer Composition - Google Patents

Antibiotic Anticancer Composition Download PDF

Info

Publication number
KR950016759A
KR950016759A KR1019930032093A KR930032093A KR950016759A KR 950016759 A KR950016759 A KR 950016759A KR 1019930032093 A KR1019930032093 A KR 1019930032093A KR 930032093 A KR930032093 A KR 930032093A KR 950016759 A KR950016759 A KR 950016759A
Authority
KR
South Korea
Prior art keywords
anticancer
present
anthracycline
anticancer agent
composition
Prior art date
Application number
KR1019930032093A
Other languages
Korean (ko)
Inventor
강흔수
주홍구
한재갑
Original Assignee
유영학
주식회사 미원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유영학, 주식회사 미원 filed Critical 유영학
Priority to KR1019930032093A priority Critical patent/KR950016759A/en
Publication of KR950016759A publication Critical patent/KR950016759A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 심장독성이 경감된 항암항생 조성물을 제공하며, 이 조성물은 유효성분으로서 안스라사이클린계 항암제와 안스라사이클린계 항암제 대하여 당량비로 0.01∼30배의 아데노신(Adenosine)을 함유함을 특징으로 한다. 본 발명의 조성물에 사용되는 안스라사이클린계 항생항암제는 독소루비신, 에퍼두비신, 다우노루비신, 피라루비신 또는 이다루비신이다.The present invention provides an anticancer antibiotic composition with reduced cardiotoxicity, and the composition contains 0.01 to 30 times of adenosine (Adenosine) in an equivalent ratio with respect to the anthracycline anticancer agent and the anthracycline anticancer agent as an active ingredient. do. The anthracycline antibiotic agent used in the composition of the present invention is doxorubicin, efferduvicin, daunorubicin, pyrarubicin or idarubicin.

본 발명의 항생항암 조성물은 그에 포함되어 있는 아데노신이 안스라사이클린제 항암제가 갖는 심장독성을 경감시키는 작용을 하며, 따라서 본 발명의 조성물은 심장독성이 경감되어 있기 때문에 종래보다 안스라사이플린게 항암제의 투여량을 높이므로써 중강된 항암작용을 발휘할 수 있다.The anticancer anticancer composition of the present invention acts to reduce the cardiotoxicity of the adenosine contained in the anticancer agent of anthracycline. Therefore, the anticancer anticancer agent of the present invention is more effective than the conventional anticancer agent because the antitoxicity of the anticancer agent of the present invention is alleviated. Increasing the dose of can exert a moderate anticancer action.

Description

항생항암 조성물Antibiotic Anticancer Composition

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (2)

유효성분으로서 안스라사이클린계 항암제와 안스라사이클린계 항암제 대하여 당량비로 0.01~30배의 아데노신(Adenosine)을 함유함을 특징으로 하는 항생항암 조성물.An anticancer composition comprising an adenosine of 0.01 to 30 times in an equivalent ratio with respect to an anthracycline anticancer agent and an anthracycline anticancer agent as an active ingredient. 제1항에 있어서, 안스라사이클린계 항암제는 독소루비신, 다우노루비신, 에피루비신, 이다루비신 또는 피라루비신에서 선택된을 특징으로 하는 항생항암 조성물.The anticancer composition according to claim 1, wherein the anthracycline anticancer agent is selected from doxorubicin, daunorubicin, epirubicin, idarubicin or pyrarubicin. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019930032093A 1993-12-31 1993-12-31 Antibiotic Anticancer Composition KR950016759A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019930032093A KR950016759A (en) 1993-12-31 1993-12-31 Antibiotic Anticancer Composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019930032093A KR950016759A (en) 1993-12-31 1993-12-31 Antibiotic Anticancer Composition

Publications (1)

Publication Number Publication Date
KR950016759A true KR950016759A (en) 1995-07-20

Family

ID=66853377

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930032093A KR950016759A (en) 1993-12-31 1993-12-31 Antibiotic Anticancer Composition

Country Status (1)

Country Link
KR (1) KR950016759A (en)

Similar Documents

Publication Publication Date Title
AU591309B2 (en) Taxol derivatives, their preparation and pharmaceutical compositions containing them
BR9712304A (en) Use of pyrazole-1-benzyl-3- (substituted hetaryl) derivatives-melts
NZ336344A (en) Endoparasiticidal and ectoparasiticidal compositions comprising an avermectin, ivermectin or milemycin with antagonists or agonists of nicotinergic acetylcholine receptors
ES2123323T3 (en) ASSOCIATION OF A COMPOUND WITH ANTIMICROBIAL ACTIVITY (FOR EXAMPLE LIPOAMINOACIDO N, N-OCTANOILGLICINA) AND OF A GLYCEROL MONO-ALKYLETER AND ITS USE AS ANTIMICROBIAL AGENT.
KR910004185A (en) Compounds and their use for reversing multidrug resistance of cancer cells against cytotoxin agents
EP0375367A3 (en) Biocidal compositions
EP0077377A4 (en) Anthracycline glycoside compositions, their use and preparation.
BR9810985A (en) Topical application of a combination of benzoyl peroxide and a second active ingredient
IE852593L (en) Compositions containing anthracycline glycosides
BR0008453A (en) Synergistically anti-tumor composition
BR9200786A (en) USE OF HYDROPHYL PENETRATION AGENTS AND DERMATOLOGICAL COMPOSITION FOR THE TREATMENT OF ONICOMYCOSIS
BR1100612A (en) Suitable saccharide consisting of two saccharides and one spacer, their use and pharmaceutical composition
ATE173738T1 (en) ALKYLTHIOALKYLAVERMECTINES ARE ACTIVE ANTIPARASITE ACTIVES
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
MX9300576A (en) IMPROVEMENTS IN GAME MATERIAL.
KR920007627A (en) Anticorrosive composition
KR950007857A (en) Rapamycin preparations for oral administration
Du et al. Glycosidic constituents from in vitro Anoectochilus formosanus
ES2133380T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ANTHRACICLINE GLYCOSIDES LINKED TO POLYMER DERIVATIVES, AND THEIR PREPARATION PROCEDURE.
KR950016759A (en) Antibiotic Anticancer Composition
KR910005876A (en) Minimal pharmaceutical compositions for the treatment of capillary weakness
KR890000009A (en) Agricultural bioactive agents
GB2002754A (en) Antitumor anthracycline antibiotics
FR2705094B1 (en) New lupane derivatives, their preparation and the pharmaceutical compositions containing them.
KR970064618A (en) TNFα activity inducing composition containing ginsenoside

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application